tepoditamab   Click here for help

GtoPdb Ligand ID: 10353

Synonyms: MCLA-117 | MCLA117 | PB9122
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds CLEC12A on myeloid cells and CD3ε on cytotoxic T cells. It is being developed by Merus as a novel therapy for acute myeloid leukemia (AML) [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
MCLA-117 has progressed to Phase 1 clinical evaluation (NCT03038230). Click here to link to ClinicalTrials.gov's full list of MCLA-117 trials.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03038230 MCLA-117 in Acute Myelogenous Leukemia Phase 1 Interventional Merus N.V.